Clinical Trials Sponsored by Sorrento Therapeutics, Inc.

Total 2949 results

Sorrento Therapeutics, Inc.

Not yet recruiting

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Sarcoma | Cancer | Solid Tumor | Cancer of Pancreas | Hepatic Metastasis
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Solid Tumor | Refractory Tumor | Relapsed Solid Neoplasm

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (BR)

Covid19
Sorrento Therapeutics, Inc.

Withdrawn

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Light Chain (AL) Amyloidosis
Sorrento Therapeutics, Inc.

Active, not recruiting

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Sorrento Therapeutics, Inc.

Active, not recruiting

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

COVID-19

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Solid Tumor, Adult | Refractory Cancer | Relapsed Solid Neoplasm
Sorrento Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 (SOC)

Covid-19

United States
Sorrento Therapeutics, Inc.

Terminated

Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases (AntiCEA_CART)

Metastatic Pancreatic Carcinoma

United States
Sorrento Therapeutics, Inc.

Active, not recruiting

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Knee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic

United States
Sorrento Therapeutics, Inc.

Terminated

Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

Covid19

Brazil
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

Covid19

United States
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

Covid19

United States
Sorrento Therapeutics, Inc.

Withdrawn

Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection (US)

COVID-19
Sorrento Therapeutics, Inc.

Recruiting

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Covid19

United States
Sorrento Therapeutics, Inc.

Recruiting

Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Mycosis Fungoides

United States
Sorrento Therapeutics, Inc.

Suspended

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Pain | Pain, Intractable | Pain Cancer

United States
Sorrento Therapeutics, Inc.

Suspended

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Cancer Metastatic

United States
Sorrento Therapeutics, Inc.

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

COVID-19

Australia
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19

Covid19

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Solid Tumor | Relapsed Solid Tumor | Refractory Tumor
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
Sorrento Therapeutics, Inc.

Withdrawn

A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee

Osteoarthritis, Knee | Knee Pain Chronic
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

Osteoarthritis, Knee | Osteo Arthritis Knee | Knee Pain Chronic
Sorrento Therapeutics, Inc.

Completed

Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19

Covid19

Brazil
Sorrento Therapeutics, Inc.

Withdrawn

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome | Ards
Sorrento Therapeutics, Inc.

Withdrawn

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Covid19
Sorrento Therapeutics, Inc.

Completed

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

Osteoarthritis, Knee | Pain, Knee

United States
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

Intractable Cancer Pain

United States
Sorrento Therapeutics, Inc.

Not yet recruiting

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Sorrento Therapeutics, Inc.

Recruiting

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Light Chain (AL) Amyloidosis

United States
Sorrento Therapeutics, Inc.

Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Diffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
Sorrento Therapeutics, Inc.

Terminated

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

Covid19

United Kingdom
Sorrento Therapeutics, Inc.

Enrolling by invitation

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Long-term Follow-up

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Malignant Tumor of Pancreas Metastatic to Liver
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19

Covid19
Sorrento Therapeutics, Inc.

Withdrawn

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Pain, Intractable | Pain Cancer
Sorrento Therapeutics, Inc.

Withdrawn

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

Covid19 | ARDS

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19

Covid19
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19

Covid-19
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Sorrento Therapeutics, Inc.
Kimberly-Clark Corporation

Completed

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (KCC-SMT-002)

Migraine Disorders

United States
Sorbent Therapeutics

Completed

Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Healthy
Sorbent Therapeutics

Completed

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

Heart Failure

United States
Sorbent Therapeutics

Unknown

Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects (STEPWISE)

Heart Failure

Israel, Argentina, United States
Sorbent Therapeutics

Completed

Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Basic Science: Safety, Tolerability, Efficacy of CLP

United States
Sorbent Therapeutics
Pharmaterra

Completed

Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

Heart Failure

Georgia, Moldova, Republic of, Armenia

3

Subscribe